Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-COVID-19: Antiviral Combinations in Mild to Critical COVID-19
NCT04303299Phase 3Completed
- Sponsor
- Ministry of Public Health
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of oseltamivir, hydroxychloroquine, lopinavir, darunavir, favipiravir in coronavirus disease 2019 (COVID-19), sponsored by Ministry of Public Health. Started Aug 2020; status: completed.
02
Drugs
oseltamivirhydroxychloroquinelopinavirdarunavirfavipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04303299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303299.